SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IGT ((VSE:IGT) Blockbuster Anti-Cancer Test Results !!!
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Solid Play who wrote ()8/6/1998 8:06:00 PM
From: jean paul sauvT  Read Replies (1) of 94
 
IND application filed for Anhydrovinblastine

IGT Pharma Inc IGT
Shares issued 8,300,000 Aug 4 close $0.95
Tue 4 Aug 98 News Release
Mr. Bruce Schmidt reports
The company has received confirmation from its regulatory consultants that
an investigational new drug application (IND) has been filed for the new
cancer drug, Anhydrovinblastine (AVLB).
The receipt and review of the application by the Bureau of Pharmaceutical
Assessment of the Health Protection Branch (HPB), in Ottawa, will provide
the necessary data and rationale to allow the start of clinical trials for
the treatment of certain lung cancers in humans. Should no deficiencies in
the application be identified by the HPB, authorization will be received
within 60 days to allow the human clinical trials to proceed.
The IND process involves investigations that include manufacturing
standards, clinical protocols, and pre-clinical biological studies. The
latter studies were conducted at the British Columbia Cancer Agency (BCCA)
in Vancouver and Roswell Park Cancer Institute (RPCI) in Buffalo, New York,
the results of which have provided pharmacology and toxicology data
relating to the use and characteristics of AVLB as a cancer therapeutic.
The reports indicate no adverse factors that would preclude a safe clinical
trial of AVLB in humans.
The Medical Oncology Department at the BCCA will be conducting the phase I
trial at the clinical site in Vancouver, British Columbia later this
summer. The clinical investigation team have been appointed consisting of
three clinical oncologists and one medical oncology investigator.
(c) Copyright 1998 Canjex Publishing Ltd. canada-stockwatch.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News